Corporate$TEVA8:00 AM ET

Teva and Sanofi's duvakitug maintains positive Phase 2b outcomes in UC and Crohn's at 44 weeks

By BORSA NewsroomPublished Oct 20, 2026, 8:00 AM EDTUpdated Oct 20, 2026, 8:00 AM EDT

duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement in UC and Crohn's at Week 44 in the Phase 2b LTE study. Dose response observed. Safety consistent with induction. Biomarker data also presented.

Sentimentbullish 85

Strongly bullish · 85 of 100

Impact70

medium · sector-wide

Confidence90%

high confidence · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

Phase 2b LTE study (NCT05668013) enrolled 130 patients (72 UC, 58 CD).